The present study aims at assessing long-term hemostatic profile of patients recovered from COVID-19 acute infection that remain asymptomatic (POST-COVID) versus patients with residual symptoms (LONG-COVID) through the employment of a commercially available new generation point-of-care viscoelastic device. The primary endpoint is based upon the hypothesis that patients with residual symptoms maintain an abnormal coagulation profile even after recovery from COVID-19.
Study Type
OBSERVATIONAL
Enrollment
102
Point-of-care viscoelastic assessment of the coagulation profile (extrinsic pathway, intrinsic pathway, fibrinogen contribution, tPA stimulated fibrinolysis)
Blood count and standard coagulation tests (INR, aPTT, fibrinogen, D-dimers, antithrombin)
Questionnaire from ISS (Istituto Superiore Sanità, the National Health Institute) about the health conditions before the acute COVID-19 infection, the disease (and the hospitalization) details and the eventual health disturbances experienced after the recovery from COVID-19 infection.
IRCCS Policlinico San Donato
San Donato Milanese, MI, Italy
ClotPro EXTEST
Extrinsic pathway of the coagulation as measured by the ClotPro (coagulation time CT, seconds; maximum clot firmness, MCF, millimeters)
Time frame: Day of the visit
ClotPro INTEST
Intrinsic pathway of the coagulation as measured by the ClotPro (coagulation time CT, seconds; maximum clot firmness, MCF, millimeters)
Time frame: Day of the visit
ClotPro FIBTEST
Fibrinogen contribution to the overall clot strength as measured by the ClotPro (maximum clot firmness, MCF, millimeters)
Time frame: Day of the visit
ClotPro TPATEST
Resistance to the fibrinolysis induced by the tPA (tissue plasminogen) as measured by the ClotPro (lysis time, LT, seconds; maximum lysis, ML, %).
Time frame: Day of the visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.